Michito Ubukata

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu et al. · Current Medical Research and Opinion · 2014 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu et al. · Current Medical Research and Opinion · 2014 · 60 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus

Yutaka Seino, Nobuya Inagaki, Masakazu Haneda et al. · Journal of Diabetes Investigation · 2014 · 54 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in <scp>J</scp> apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study

Rimei Nishimura, Takeshi Osonoi, Shigeto Kanada et al. · Diabetes Obesity and Metabolism · 2015 · 49 citations · Full text

Medicine, Endocrinology, Pharmacology +13

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Yutaka Seino, Kohei Kaku, Nobuya Inagaki et al. · Endocrine Journal · 2015 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17